New Data in HFpEF

The podcast explores the complexities of heart failure with preserved ejection fraction (HFpEF), highlighting challenges in diagnosis due to overlapping comorbidities in older patients. It emphasizes the importance of identifying underlying causes and tailoring treatments accordingly, rather than relying solely on ejection fraction measurements. The discussion covers the EMPEROR-Preserved trial, noting its positive outcomes regarding heart failure hospitalizations and the significance of early intervention with SGLT-2 inhibitors. The podcast further examines the varying effectiveness of treatments based on ejection fraction ranges, suggesting a need for personalized approaches in managing HFpEF.

Outlines

Part 1: Introduction, Definitions, and Staging

Part 2: Pathophysiology and Historical Trials

Part 3: EMPEROR-Preserved Trial Analysis

Part 4: Clinical Application and Future Outlook

Sign in to continue reading, translating and more.

Open full episode in Podwise

CorConsult Rx: Evidence-Based Medicine and Pharmacy

Part 1: Introduction, Definitions, and Staging

Introduction to Guests and HFpEF: Prevalence, Challenges, and Background

Defining HFpEF: Symptoms, Ejection Fraction Ranges, and Future Classifications

Staging Heart Failure: Transitioning from NYHA to a Risk-Based Approach

Part 2: Pathophysiology and Historical Trials

Pathophysiology of HFpEF: Comorbidities, Inflammation, and the Neurohormonal Hypothesis

HFpEF Trials: iPreserve, TopCat, and the Importance of Subgroup Analysis

Part 3: EMPEROR-Preserved Trial Analysis

EMPEROR-Preserved Trial: Design, Inclusion Criteria, and Baseline Characteristics

EMPEROR-Preserved Results: Early Benefits and Ejection Fraction Thresholds

Part 4: Clinical Application and Future Outlook

Access to SGLT2 Inhibitors, Future Trials, and Key Take-Home Points for HFpEF

New Data in HFpEF

CorConsult Rx: Evidence-Based Medicine and Pharmacy

Part 1: Introduction, Definitions, and Staging

00:12Introduction to Guests and HFpEF: Prevalence, Challenges, and Background

Introduction to Guests and HFpEF: Prevalence, Challenges, and Background

04:52Defining HFpEF: Symptoms, Ejection Fraction Ranges, and Future Classifications

Defining HFpEF: Symptoms, Ejection Fraction Ranges, and Future Classifications

10:32Staging Heart Failure: Transitioning from NYHA to a Risk-Based Approach

Staging Heart Failure: Transitioning from NYHA to a Risk-Based Approach

Part 2: Pathophysiology and Historical Trials

17:52Pathophysiology of HFpEF: Comorbidities, Inflammation, and the Neurohormonal Hypothesis

Pathophysiology of HFpEF: Comorbidities, Inflammation, and the Neurohormonal Hypothesis

25:51HFpEF Trials: iPreserve, TopCat, and the Importance of Subgroup Analysis

HFpEF Trials: iPreserve, TopCat, and the Importance of Subgroup Analysis

Part 3: EMPEROR-Preserved Trial Analysis

37:39EMPEROR-Preserved Trial: Design, Inclusion Criteria, and Baseline Characteristics

EMPEROR-Preserved Trial: Design, Inclusion Criteria, and Baseline Characteristics

47:01EMPEROR-Preserved Results: Early Benefits and Ejection Fraction Thresholds

EMPEROR-Preserved Results: Early Benefits and Ejection Fraction Thresholds

Part 4: Clinical Application and Future Outlook

55:23Access to SGLT2 Inhibitors, Future Trials, and Key Take-Home Points for HFpEF

Access to SGLT2 Inhibitors, Future Trials, and Key Take-Home Points for HFpEF